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Abstract: We studied uterine myomas originating from females of reproductive age and from females of peri-
menopausal age. Uterine myomas represent benign tumors of the myometrium, and they develop frequently in
women of reproductive age. The frequency of uterine myomas increases with age until women reach the meno-
pause. The study included patients with a myomatous uterus, in the reproductive age or peri-menopausal age,
independently evaluating small and large myomas. Myometrial alterations in their direct vicinity were evaluated
independently of the myomas. The study included evaluation of immunolocalization of two index proteins which
participate in myoma cells growth control: Ki-67 nuclear antigen and caspase 3. In women of reproductive age,
both in small and large myomas, elevated immunostaining of Ki-67 was noted in parallel to low levels of caspase 3
staining, which indicated the ongoing process of proliferation. In women of peri-menopausal age with small or
large myomas, no Ki-67 immunostaining was detected, while staining of caspase 3 manifested low levels. Prolif-
eration in reproductive age women myomas is higher than in the peri-menopausal age. (Folia Histochemica et
Cytobiologica 2011; Vol. 49, No. 3, pp. 398–404)
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Introduction
Despite their frequent manifestation, little data is
available regarding the growth and development of
leiomyomas. Based on studies of the activity of glu-
cose-6-phosphate dehydrogenase, and cytogenetic
studies, all leiomyomas are thought to reflect clonal
expansion of a single myocyte [1]. Similarly to other
tumors, probably numerous sensitive genetic targets
are present, the lesions of which lead to dysregula-
tion of a smooth muscle cell, resulting in its transfor-
mation to the common phenotype of a leiomyoma.
Despite the limited knowledge about the specific
events leading to the development of leiomyomas,
they have been shown to represent hormone-sensi-
tive tumors [2–6]. Case descriptions and studies orig-
inating from the late 1970s demonstrated that leiomy-
omas appear at the start of the reproductive age; they
grow under the influence of sex steroids and regress
following the menopause [7]. Nevertheless, the roles
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of steroids and other growth factors in the initiation
and growth of the tumors remain incompletely un-
derstood [8]. Most probably, the neoplastic transfor-
mation of smooth muscle cells to leiomyoma involves
somatic mutations of genes playing roles in prolifera-
tion and apoptosis in a normal myometrium and in
complex interactions between sex steroids and growth
factors. However, the observations provided investi-
gators with an insight into leiomyoma pathophysiol-
ogy and represented the first step for understanding
the growth potential of the ovarian steroid-dependent
tumors [2, 3, 9].
Extensive knowledge has accumulated on the role
of hormones in the growth of leiomyomas. Particular
attention has been devoted to the role of steroid sex
hormones, estrogens and progesterone in the patho-
physiology of leiomyomas and to the relationship be-
tween the hormones and known leiomyoma growth
factors. Attempts have been made to indicate possi-
ble therapeutic advantages by taking into consider-
ation other observations of leiomyoma growth under
the influence of modulators of sex steroid receptors
and their antagonists [2, 10–12].
Caspase 3, owing to its specificity and sensitivi-
ty, represents a reliable marker of cells undergo-
ing the process of programmed cell death. Low lev-
els of caspase 3 may indicate partial inhibition of
apoptosis. Activation of the latter process takes
place following cell stimulation to apoptotic death,
which leads to cell destruction and apoptotic cell
death [13–15].
Two index proteins, which participate in growth
control in leiomyoma monoclonal cells, have been
evaluated. Ki-67 and caspase 3 have been selected,
which are helpful in evaluation of the course and
characteristics of the uterine leiomyoma neoplas-
tic processes. In order to implement the goal, we
have aimed at demonstrating the importance of the
evaluation of differences in expression of the se-
lected proteins in tissues of the myometrium and
of leiomyoma.
The chief aim of our study was to resolve the prob-
lem of how the proliferative potential and intensity
of apoptotic processes differ between the myometri-
um of healthy females and females in whom leiomyo-
mas have been demonstrated. Moreover, we com-
pared the profiles between small and large myomas
to determine how the age of the patient affects the
proliferative and apoptotic processes in the disease.
Since most myomatous women remain under per-
manent supervision, and are not immediately subject-
ed to surgery, any additional information is particu-
larly important, as it would allow for non-invasive
monitoring of this common disease.
Material and methods
Material. Recruitment of the patients and their clinical stud-
ies were conducted in the Chair and Department of Gyne-
cological Oncology, Silesian Medical School in Katowice,
while the studies related to protein localization were per-
formed in the Department of Proteomics, Medical Univer-
sity of Silesia in Sosnowiec.
The studies included ten patients of reproductive age
with no leiomyomas and ten patients of peri-menopausal
age. The patients provided the lesion-free controls. More-
over, the study included 40 reproductive age patients with
uterine leiomyomas (below 45 years of age, FSH < 30 mIU/
/ml; samples were taken in follicular phase of menstrual
cycle) and 40 peri-menopausal age patients with uterine
leiomyomas (45–55 years of age, FSH > 30 mIU/ml). In
each case, the group of 40 patients provided 20 prepara-
tions of small leiomyomas and 20 preparations of large
leiomyomas.
The experimental material was sampled during surgery.
It included a leiomyoma sample of 1 × 0.5 cm and a sample
of healthy tissue of a similar size, taken at a distance of no
less than 4 cm from the margins of the myoma (the autolo-
gous control). The material was immediately placed in neu-
tral buffered formalin.
The study protocol was approved by the Ethical Com-
mission, Silesian Medical University in Katowice.
Characteristics of studied groups. Group 1 — myometri-
um of menstruating women, in whom hysterectomy was
performed for reasons other than uterine leiomyomas; the
ten patients represented the lesion-free control; Group 2
— leiomyomas of < 3 cm in diameter, sampled from the
uteri of menstruating women (n = 20); Group 3 — myo-
metrium of menstruating women, sampled at a distance of
no less than 4 cm from the margins of a small leiomyoma
(n = 20; autologous control); Group 4 — leiomyomas of
> 5 cm in diameter, sampled from the uteri of menstruating
women (n = 20); Group 5 — myometrium of menstruating
women, sampled at a distance of no less than 4 cm from the
margins of a large leiomyoma (n = 20; autologous control);
Group 6 — myometrium of non-menstruating women, in
whom hysterectomy was performed for reasons other than
uterine leiomyomas (n = 10; lesion-free control); Group 7
— leiomyomas of < 3 cm in diameter, sampled from the
uteri of non-menstruating women (n = 20); Group 8 —
myometrium of non-menstruating women, sampled at a dis-
tance of no less than 4 cm from the margins of a large lei-
omyoma (n = 20; autologous control); Group 9 — leiomy-
omas of > 5 cm in diameter, sampled from the uteri of non-
-menstruating women (n = 20); Group 10 — myometri-
um of non-menstruating women, sampled at a distance of
no less than 4 cm from the margins of a large leiomyoma
(n = 20, autologous control).
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Histology. The tissue samples were fixed in 4% (v/v) solu-
tion of buffered formalin, for 24 h, at 4°C, dehydrated,
cleared in xylenes and embedded in paraffin.
Sections (5 μm) were mounted on silane-coated slides,
de-waxed, and rehydrated. The review preparations were
stained with hematoxylin and eosin (H-E).
Immunohistochemical studies. Detection of apoptosis
undergoing cells took advantage of immunohistochemical
tests, employing polyclonal rabbit antibodies to the active
form of caspase 3 (Abcam, Cambridge, UK) and for detec-
tion of dividing cells mouse monoclonal antibodies were
used against the nuclear Ki-67 antigen (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA).
To unmask the antigens, sections were incubated in
a water bath at a temperature of 95°C in Tris-EDTA solution,
pH 9.0 for 30 min and, then cooled at room temperature.
Endogenous peroxidase activity was quenched using 1.5%
(v/v) solution H2O2 in methanol for 10 min and then slides
were washed in PBS-Tween 20 (0.05% v/v) and blocked with
1% BSA for 60 min.
After this, the slides were incubated with appropriate
primary antibodies. The incubation was conducted over-
night, at a temperature of 4°C. The ABC technique was
employed to visualize the bound primary antibodies. After
washing in PBS-Tween-20, sections were incubated with bi-
otinylated goat anti-rabbit or horse anti-mouse immuno-
globulins (Vector Laboratories Inc.) for 30 min, and were
incubated with avidin-biotinylated peroxidase complex (Vec-
tor) for 30 min. Diaminobenzidine (DAB) and H2O2 in PBS,
pH 7.5 were used as peroxidase substrates (Vector). Final-
ly, the tissues were stained with Gill’s hematoxylin, dehy-
drated, and cover-slipped. For negative controls, rabbit or
mouse IgG were used.
Archives. Photographic documents were prepared using
a light microscope with a photographic attachment. In or-
der to accentuate the immune reactions, every reaction was
documented by 10 photographs under × 200 magnification
(× 20 objective and × 10 ocular) using a digital camera-
equipped Nikon microscope.
Evaluation of immune reaction. In microscope prepara-
tions of every experimental group, labelled cells were scored,
in which caspase 3 expression or cell nuclei with Ki-67 ex-
pression was demonstrated.
Results
Ki-67 nuclear antigen
In control uterine sections, originating from women
with no diagnosed leiomyomas, either at reproduc-
tive age (Group 1) or peri-menopausal age (Group 6),
immunolocalization of Ki-67 was observed only spo-
radically (Figures 1A, F). At magnification × 400,
only one positive cell nucleus could be seen per mi-
croscope field. The labelled cell nuclei represented
mainly cell nuclei of cells in connective tissue stroma.
In the experimental group in which leiomyomas
originated from the uteri of women of reproductive
age, immunolocalization of Ki-67 was noted in 12 prep-
arations per 20 cases of small leiomyomas (Group 2;
Figure 1B) and in four preparations per 20 cases of
large leiomyomas (Group 4; Figure 1D).
In the group of young women, the number of la-
belled cells per microscope field was higher compared
to the control. On average, three cell nuclei were pos-
itive in eight preparations, and four cell nuclei were
positive in four preparations per 20 examined prepa-
rations (Figure 1B). It should be recorded that simi-
lar results were obtained in preparations originating
from the vicinity of leiomyomas (Group 3; Figure 1C).
The dividing cells included, mainly, endothelial cells
and myocytes. In preparations representing large
myomas, on average four positive cells nuclei were
detected per microscope field (Figure 1D), while in
their vicinity just three positive cell nuclei were de-
tected per microscope field (autologous control;
Group 5; Figure 1E). In large leiomyomas, dividing
myocytes prevailed, whereas in their vicinity dividing
endothelial cells prevailed.
In preparations representing leiomyomas originat-
ing from peri-menopausal women, practically no Ki-67
immunolocalization was observed (just individual
positive cell nuclei per preparation), independently
of the size of leiomyoma (Groups 7 and 9; Figures
1G, I). Also no positive reaction could be detected in
preparations representing the vicinity of leiomyoma
(autologous control; Groups 8 and 10; Figures 1H, J).
Caspase 3
In control groups, apoptosis could be detected in both
age groups, but it was more frequent in the myometria
of young women (Group 1), involving 3–5 cells per vi-
sual field in every preparation (Figure 2A). In cases of
peri-menopausal women (Group 6), on average six
cases demonstrated a single cell and four cases two
cells per visual field, respectively (Figure 2F).
In the research groups in all cases including 20
cases of various size leiomyomas, originating from
women of reproductive age, immunolocalization of
caspase 3 was detected in eight cases of small leiomy-
omas (Group 2; Figure 2B) and in 16 cases of large
leiomyomas (Group 4; Figure 2D). In every case,
however, no more than 1–2 cells undergoing apopto-
sis could be noted per visual field. A similar degree
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Figure 1. Immunohistochemical staining of uterine
samples from women of reproductive (A–E) and perime-
nopausal (F–J) age with mouse anti-Ki-67 monoclonal
antibodies. A and F — healthy myometrium; B and G —
small myomas; C and H — periphery of small myomas;
D and I — large myomas; E and J — periphery of large
myomas
Figure 2. Immunohistochemical staining of uterine
samples from women of reproductive (A–E) and perime-
nopausal (F–J) age with rabbit anti-caspase-3 polyclonal
antibodies. A and F — healthy myometrium; B and G —
small myomas; C and H — periphery of small myomas;
D and I — large myomas; E and J — periphery of large
myomas
of immunological staining was also detected in the
vicinity of the leiomyomas (autologous control;
Groups 3 and 5; Figures 2C, E). It should be stressed
that the apoptosis was not accompanied by prolifera-
tion: no immunolocalization of Ki-67 was detected in
leiomyomas manifesting apoptosis.
In the group of uterine leiomyomas originating from
peri-menopausal women, immunolocalization of
caspase 3 was noted only in cases of small leiomyomas
(Group 7; Figure 2G) and in their vicinity (autologous
control; Group 8; Figure 2H). Expression of the caspase
ranged from one to two cells per visual field in cases of
preparations representing the vicinity of leiomyoma,
and at most a single cell in the leiomyoma tissue.
In summary, if they are manifested, proliferation
processes (Ki-67 expression) can be noted only in
myomas of women of reproductive age while apopto-
sis (active caspase 3 expression) does not develop in
large myomas of women of perimenopausal age.
Myometrium sampled close to a myoma manifests
levels of proliferation and apoptosis similar to those
seen in myoma tissue.
402 A Plewka et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2011
10.5603/FHC.2011.0056
www.fhc.viamedica.pl
Discussion
Among the evaluated indices related to links between
apoptosis and cell proliferation, no immunolocalization
of Ki-67 was detected in the control. This has been the
case in both cases of samples originating from patients
of reproductive age and postmenopausal women.
In the same samples, a well-marked activity of
caspase 3 has been documented. Its level has been
found to slightly vary depending on the age of the
women: in the older group, the reaction for caspase 3
proved to be more intense. The pattern of immuno-
cytochemical reactions changed in the myometrial
samples obtained from women in whom leiomyoma-
ta had been detected. In all cases, a weak or a very
weak immunolocalization of the two examined pro-
teins was found. The alterations became even more
accentuated: the activity of caspase 3 practically dis-
appeared in leiomyomas, independently of the age
group or leiomyoma size. Nevertheless, in the groups
immunolocalization of Ki-67 has been noted to change
as a function of age. In leiomyomas originating from
young women, activity of Ki-67 has been detected even
if its level has been low and has shown no relation-
ship to the size of leiomyomas. The index of cell pro-
liferation has been, however, absent in samples orig-
inating from post-menopausal women.
The absence of Ki-67 antigen points to the absence
of growth signals. On the other hand, high immun-
ostaining of caspase 3 in young women indicates the
presence of apoptosis. In this case this reflects a phys-
iological process, linked to phases of the menstrual
cycle. In older women, expression of caspase 3 has
been less pronounced since body senescence is ac-
companied by a decreased ability to induce apoptosis
[16]. The decreased propensity to programmed cell
death may reflect low levels of p53 and a high level of
anti-apoptotic Bcl-2. Activity of caspase 3 cannot be
detected before apoptosis; it grows in the course of
apoptosis, beginning at its early stage, and it disap-
pears again at later stages of apoptosis [13].
The results point to inhibition of apoptosis in lei-
omyomas obtained from women, whether they are in
the reproductive period or not. However, the data on
Ki-67 suggests that proliferative processes take place
only in young women. In such cases the size of the
leiomyoma is irrelevant. Nevertheless, such argumen-
tation must be very cautious and results related to
the problem must be accompanied by an appropriate
comment.
Regrettably, it should also be borne in mind that
the proliferation-associated antigen manifests also its
drawbacks: the amount of Ki-67 abruptly decreases
following termination of mitosis. The protein is prac-
tically undetectable in cells at G0 phase of cell cycle,
which is linked to its half-life. Ki-67 protein cannot
be detected in cells which remain out of the active
cell cycle. For this reason, Ki-67 is thought to repre-
sent a reliable index of cell proliferation [17]. Never-
theless, certain problems have been noted related to
the use of Ki-67 antigen as a prognostic index. The
first of them involves the fact that the level of Ki-67
antigen expression is affected by the accessibility of
nutrients for the cell. In cells devoid of such nutri-
ents, no Ki-67 antigen presence can be detected. Lei-
omyoma cells, among others, are such cells. For ex-
ample, examination of a tissue sample taken from the
middle of a large leiomyoma with necrotic lesions may
provide a falsely low level of the examined Ki-67 an-
tigen. In turn, most tumors consist of a differentiated
cell population, which may differ in expression levels
of various proteins, including Ki-67. For example, two
different samples isolated from the same tumor were
examined for the presence of Ki-67 antigen and two
clearly distinct values were obtained of proliferation
index based on the protein.
Some authors have expressed reservations regard-
ing the use of Ki-67 antigen as a cell proliferation in-
dex. Van Oijen et al. [18] and Ioachim [19] demon-
strated that the protein can also be detected in cells
in which the cell cycle was blocked. Already such in-
formation indicates that cells with Ki-67 antigen ex-
pression do not always remain in the active cell cycle.
Reservations remain as to the use of Ki-67 antigen as
an index of cell proliferation since most tumors con-
sist of a differentiated cell population, which may dif-
fer in levels of expression of various proteins, includ-
ing Ki-67 antigen. Occasionally, the number of pro-
liferating cells estimated on the basis of Ki-67 anti-
gen presence can be overestimated. A situation is also
possible in which proliferating cells yield a negative
result of the analysis. Analysis of MCM protein ex-
pression represents a more sensitive marker, mark-
edly better than the currently employed convention-
al proliferation indices (Ki-67, PCNA) [4]. The
studies demonstrated that application of antibod-
ies directed against MCM proteins is more advan-
tageous since, using such antibodies, higher num-
bers of cells were identified as present in the active
cell cycle than those documented using PCNA or
Ki-67. Further studies and analysis will be required
to clarify whether or not such reservations also per-
tain to leiomyomas.
Cells of leiomyomas, compared to the surround-
ing smooth muscle cells, contain a much higher den-
sity of estrogen receptors. Estrogens synthesized in
leiomyoma cells boost proliferation, mainly due to
stimulation of aromatase activity, the expression of
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which is much higher in leiomyoma cells than in the
tumor-surrounding smooth muscles. The presence of
Ki-67 antigen outside the leiomyoma may indicate
continuing hyperplasia of the tumor [20–24].
The absence of Ki-67 antigen in leiomyomas of
females at the peri-menopausal age suggests the in-
hibition of proliferation might have been induced by
the absence of stimulation by ovarian estrogens. The
estrogens localized in tumor cells originate from aro-
matization and act locally as a mitogenic factor, ex-
erting a promotional effect until a certain moment,
following which estrogen concentration becomes nor-
malized and stable. The absence of Ki-67 antigen also
allows another conclusion to be reached: the tumor
remains in a condition of equilibrium, devoid of nu-
trients and of growth factors. This reflects the absence
of blood vessels in the neighbourhood of descendant
cells. The low level of caspase 3 expression points to
the undergoing apoptotic process, probably resulting
in a reduction in tumor mass [14].
Uterine leiomyomas are known to be the most fre-
quent tumors of the female genital tract. Indepen-
dently of the usual uterine leiomyomas or leiomyosa-
rcomas, a spectrum of intermediate uterine smooth
muscle tumors has been documented, with overlap-
ping characters. It remains unclear whether, at the
level of pathogenesis, the intermediate tumors reflect
transition from one marginal situation of common
benign leiomyomas to the other extreme of uterine
leiosarcomas [25, 26].
The challenge following diagnosis of uterine lei-
omyoma involves prognostic qualification of the case.
It should be kept in mind that histopathological and
clinical traits of benign and malignant tumors do not
necessarily correlate with each other. The morpho-
logical traits remain as valuable as their capacity to
predict clinical outcome within the accepted range of
reliability. In most cases, leiomyoma cases are easily
categorised as benign or malignant tumors. In such
cases, morphological traits allow the reliable predic-
tion of clinical behaviour. In other cases, however,
correlation of morphological patterns with clinical
prognosis remains a significant challenge [27, 28].
Evaluation of basic leiomyoma traits with usual
differentiation should incorporate the key prognos-
tic markers, such as presence or absence of coagula-
tive necrosis, of moderate or severe atypia and mitot-
ic index. Only following completion of such a list can
an attempt be undertaken to evaluate clinically sig-
nificant categories of leiomyomas.
If the mitotic index remains below 5 cell divisions
per 10 high magnification microscope fields, the tu-
mor is categorized as leiomyoma. A typical leiomyo-
ma is usually well demarcated and white. At the mi-
croscopic level, tumor cells resemble the surround-
ing uterine muscle cells, except that they are more
crowded and the large ones have larger cell nuclei.
Additional immunohistochemical techniques have
been employed to evaluate cases of unreliable histol-
ogy [29–31]. Immune staining for Ki-67 may be use-
ful in distinguishing leiosarcomas and tumors of un-
certain and unknown malignant potential (STUMP)
or uterine leiomyomas [32–34]. This can be exempli-
fied by Mayerhofer et al. [35] and Lee et al. [36], who
demonstrated expression of Ki-67 in every other prep-
aration with uterine leiomyosarcomas, but in none of
the examined cases of STUMP. In numerous studies,
cell cycle proteins other than Ki-67 have been exam-
ined. For example, expressions of cyclins (E and A)
were clearly augmented in leiomyosarcomas com-
pared to leiomyomas and STUMP. Similar observa-
tions have been conducted in the cases of p16 pro-
tein, progesterone receptor and metalloproteinase-2
[37–39]. These and other studies represent strong fac-
tors which allow prediction of prognosis.
At present, the decision as to how to categorize
uterine tumors of smooth muscle cells, which on the
one hand differ from the most evident uterine lei-
omyomas, and on the other hand from leiomyosarco-
mas, continues to depend on the fixed conventional
criteria. Determination of tumor category should also
reflect clinical criteria and not just routine procedures.
A multi-stage approach is required for more accu-
rate clinical prognosis. It encompasses linking basic
clinical data, intraoperative and macroscopic obser-
vations, numerous morphological criteria and the re-
sults of immunohistochemical tests.
In our opinion, in the future, with the accumulation
of cases with specific clinical outcomes and morpholog-
ical traits, and under the influence of a growing amount
of data on molecular indices, the prognosis for manage-
ment of such tumors will become much more objective.
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